GSK Investigational Site

Zaporizhia 69076

0 studies enrolling now · 12 studies all time

What they study most

Asthma, Carcinoma, Hepatocellular, Pulmonary Disease, Chronic Obstructive

Studies at this site

• Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma — Completed
• Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control — Completed
• 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics — Completed
• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD — Completed
• 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease — Completed
• Asthma Exacerbation Study — Completed
• An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma. — Completed
• Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily — Completed
• A Dose-ranging Study of Fluticasone Furoate (FF) — Completed
• Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children — Completed